Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

OBJECTIVE: To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and KRAS mutations in these patients. METHODS: This was a single-center, randomized, open-label, prospective trial. Eight...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jack P., Wu, Chen-Yi, Yeh, Yi-Cheng, Shyr, Yi-Ming, Wu, Ying-Ying, Kuo, Chen-Yu, Hung, Yi-Ping, Chen, Ming-Huang, Lee, Wei-Ping, Luo, Jiing-Chyuan, Chao, Yee, Li, Chung-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627242/
https://www.ncbi.nlm.nih.gov/pubmed/26046796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627242/
https://www.ncbi.nlm.nih.gov/pubmed/26046796

Ejemplares similares